<?xml version="1.0" encoding="UTF-8" standalone="no"?>
<ibecs-document>
<record>
<header>
<identifier>ibc-71263</identifier>
<setSpec>1137-6627</setSpec>
</header>
<metadata xmlns="http://example.org/myapp/" xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:dcterms="http://purl.org/dc/terms/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://example.org/myapp/schema.xsd">
<dc:description xml:lang="en">The degree of anticoagulation obtained during oral anticoagulation therapy with vitamin K antagonists (VKA) varies among patients due to individual and environmental factors. The rate of anticoagulation influences the hemorrhagic risk. Therefore, it is plausible that patients specially sensitive to oral anticoagulants are at higher hemorrhagicc risk, specially during the first weeks. The role of a series of polymorphisms of the enzymes involved in the metabolism of VKA or in the vitamin K cycle are reviewed. Three polymorphisms, two in the cytochrome P450 2C9 and one in the VKORC1 enzyme, are responsible for a high portion of the variability observed in the sensitivity to AVK. Although the available literature suggests that these genetic variants could increase the risk of severe hemorrhage, larger, well designed studies are needed to confirm this notion (AU)</dc:description>
<dc:creator>Montes, R</dc:creator>
<dc:creator>Zozaya, J</dc:creator>
<dc:creator>Hermida, J</dc:creator>
<dc:creator>Nantes, O</dc:creator>
<dc:creator>Molina, E</dc:creator>
<dc:language>es</dc:language>
<dc:description xml:lang="es">La anticoagulación conseguida durante el tratamiento con anticoagulantes orales antagonistas de la vitamina K (AVK) varía entre unos pacientes y otros debido a factores individuales y ambientales. La intensidad de la anticoagulación condiciona el riesgo hemorrágico. Por tanto, es probable que los pacientes especialmente sensibles a los AVK corran un riesgo hemorrágico mayor, especialmente durante las primeras semanas. En esta revisión se va a discutir el papel de una serie de polimorfismos de las enzimas involucradas en la metabolización de los AVK o en el ciclo de la vitamina K. Dos polimorfismos del citocromo P450 2C9 y uno de la enzima VKORC1 son responsables de un alto porcentaje de la variabilidad observada en la sensibilidad a los AVK. Aunque parece que dichas alteraciones genéticas se asocian con el riesgo de experimentar una hemorragia severa, confirmar este extremo requerirá estudios más amplios y mejor diseñados (AU)</dc:description>
<dc:source>An Sist Sanit Navar;31(3): 247-258, sept.-dic. 2008. ilus</dc:source>
<dc:identifier>ibc-71263</dc:identifier>
<dc:subject>^d29611</dc:subject>
<dc:subject>^d6622^s22033</dc:subject>
<dc:subject>^d3595^s22007</dc:subject>
<dc:subject>^d932^s22062</dc:subject>
<dc:subject>^d932^s22073</dc:subject>
<dc:subject>^d11547^s22031</dc:subject>
<dc:subject>^d3595^s22033</dc:subject>
<dc:subject>^d11547^s22021</dc:subject>
<dc:subject>^d15213^s22073</dc:subject>
<dc:subject>^d3595^s22062</dc:subject>
<dc:type>article</dc:type>
<dc:date>200812</dc:date>
</metadata>
</record>
</ibecs-document>
